Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapyAkane Inoue‐Yamauchi(Memorial Sloan Kettering Cancer Center), Emily H. Cheng(Memorial Sloan Kettering Cancer Center)Nature CommunicationsJuly 17, 201710.1038/ncomms16078Cited by 174SaveCiteExport RISWatch citationsRelated PapersSETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis|JCI Insight|2023|22